Trial Profile
An exploratory Clinical study of Apatinib combined with etoposide in the treatment of recurrent small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Aug 2018
Price :
$35
*
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Brain metastases; Small cell lung cancer
- Focus Therapeutic Use
- 04 Aug 2018 New trial record